Foghorn Therapeutics Unveils Strong Preclinical Oncology Data at AACR for Multiple Programs

summarizeSummary

Foghorn Therapeutics presented robust preclinical data at the AACR Annual Meeting, demonstrating complete tumor regression for its lead candidate FHD-909 and strong results for multiple degrader programs, significantly bolstering its oncology pipeline.

check_boxKey Events

• Compelling Preclinical Data for FHD-909

  The SMARCA2 selective inhibitor FHD-909 demonstrated complete and durable tumor regression, along with anti-tumor immune memory, when combined with an anti-PD-1 antibody in preclinical syngeneic mouse models. This is a strong positive signal for the lead candidate currently in Phase 1.

• Positive Results for Selective CBP Degrader

  The selective CBP degrader FHT-171 showed strong anti-tumor activity as a monotherapy and a favorable tolerability profile in preclinical models of heavily pretreated ER+ breast cancer, indicating potential for a new therapeutic option.

• Superior Efficacy for Selective EP300 Degrader

  Foghorn's selective EP300 degrader outperformed a clinical benchmark (inobrodib) in preclinical multiple myeloma models, demonstrating enhanced safety and efficacy, including tumor regression in pomalidomide-resistant models.

• Progress with Selective ARID1B Degrader

  The company reported robust degradation with its cereblon-based selective ARID1B degraders, designed for potential oral bioavailability, marking progress on this previously intractable target for ARID1A-mutant cancers.

auto_awesomeAnalysis

Foghorn Therapeutics announced compelling preclinical data for its lead SMARCA2 inhibitor, FHD-909, showing complete and durable tumor regression with immune memory in combination with an anti-PD-1 antibody. This is a significant positive development for their oncology pipeline, especially as FHD-909 is already in Phase 1. Additionally, the company reported favorable efficacy and tolerability for its selective CBP degrader in ER+ breast cancer models and superior efficacy for its selective EP300 degrader in multiple myeloma compared to a clinical benchmark. Progress with the selective ARID1B degrader program further strengthens the pipeline. These results, presented at AACR, provide strong validation for Foghorn's chromatin regulatory system platform and could de-risk future clinical development, potentially attracting further investment or partnerships. The company also noted a cash runway into H1 2028, providing financial stability for these advancements.